Olfactory ensheathing cells improve the survival of porcine neural xenografts in a Parkinsonian rat model
- PMID: 31777103
- DOI: 10.1111/xen.12569
Olfactory ensheathing cells improve the survival of porcine neural xenografts in a Parkinsonian rat model
Abstract
Background: Parkinson's disease (PD) features the motor control deficits resulting from irreversible, progressive degeneration of dopaminergic (DA) neurons of the nigrostriatal pathway. Although intracerebral transplantation of human fetal ventral mesencephalon (hfVM) has been proven effective at reviving DA function in the PD patients, this treatment is clinically limited by availability of hfVM and the related ethical issues. Homologous tissues to hfVM, such as porcine fetal ventral mesencephalon (pfVM) thus present a strong clinical potential if immune response following xenotransplantation could be tamed. Olfactory ensheathing cells (OECs) are glial cells showing immunomodulatory properties. It is unclear but intriuging whether these properties can be applied to reducing immune response following neural xenotransplantation of PD.
Methods: To determine whether OECs may benefit neural xenografts for PD, different compositions of grafting cells were transplanted into striatum of the PD model rats. We used apomorphine-induced rotational behavior to evaluate effectiveness of the neural grafts on reviving DA function. Immunohistochemistry was applied to investigate the effect of OECs on the survival of neuroxenografts and underlying mechanisms of this effect.
Results: Four weeks following the xenotransplantation, we found that the PD rats receiving pfVM + OECs co-graft exhibited a better improvement in apomorphine-induced rotational behavior compared with those receiving only pfVM cells. This result can be explained by higher survival of DA neurons (tyrosine hydroxylase immunoreactivity) in grafted striatum of pfVM + OECs group. Furthermore, pfVM + OECs group has less immune response (CD3+ T cells and OX-6+ microglia) around the grafted area compared with pfVM only group. These results suggest that OECs may enhance the survival of the striatal xenografts via dampening the immune response at the grafted sites.
Conclusions: Using allogeneic OECs as a co-graft material for xenogeneic neural grafts could be a feasible therapeutic strategy to enhance results and applicability of the cell replacement therapy for PD.
Keywords: olfactory ensheathing cell; porcine ventral mesencephalon; rat model of Parkinson's disease; xenograft.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
KA-bridged transplantation of mesencephalic tissue and olfactory ensheathing cells in a Parkinsonian rat model.J Tissue Eng Regen Med. 2017 Jul;11(7):2024-2033. doi: 10.1002/term.2098. Epub 2015 Oct 29. J Tissue Eng Regen Med. 2017. PMID: 26510988
-
The Effect of Sertoli Cells on Xenotransplantation and Allotransplantation of Ventral Mesencephalic Tissue in a Rat Model of Parkinson's Disease.Cells. 2019 Nov 11;8(11):1420. doi: 10.3390/cells8111420. Cells. 2019. PMID: 31718058 Free PMC article.
-
Olfactory ensheathing cell transplantation restores functional deficits in rat model of Parkinson's disease: a cotransplantation approach with fetal ventral mesencephalic cells.Neurobiol Dis. 2004 Aug;16(3):516-26. doi: 10.1016/j.nbd.2004.04.014. Neurobiol Dis. 2004. PMID: 15262263
-
CNS immunological modulation of neural graft rejection and survival.Neurol Res. 1996 Aug;18(4):297-304. doi: 10.1080/01616412.1996.11740425. Neurol Res. 1996. PMID: 8875445 Review.
-
How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?Neurosci Bull. 2007 Nov;23(6):377-82. doi: 10.1007/s12264-007-0056-4. Neurosci Bull. 2007. PMID: 18064069 Free PMC article. Review.
Cited by
-
Combined cell-based therapy strategies for the treatment of Parkinson's disease: focus on mesenchymal stromal cells.Neural Regen Res. 2023 Mar;18(3):478-484. doi: 10.4103/1673-5374.350193. Neural Regen Res. 2023. PMID: 36018150 Free PMC article. Review.
-
C18:0 GM3 ganglioside's efficacy in LPS-induced parkinsonism: neuroprotection, inflammatory inhibition and gliosis mitigation.Behav Brain Funct. 2025 Jul 26;21(1):25. doi: 10.1186/s12993-025-00289-8. Behav Brain Funct. 2025. PMID: 40713782 Free PMC article.
-
Research progress of cell treatment strategy in Parkinson's disease.Neurosci Appl. 2024 Mar 30;3:104061. doi: 10.1016/j.nsa.2024.104061. eCollection 2024. Neurosci Appl. 2024. PMID: 40656068 Free PMC article. Review.
-
Assessment of the anti-nociceptive effects of fetal ventral mesencephalic tissue allografts in a rat model of hemi-Parkinson's disease using fMRI.Front Aging Neurosci. 2022 Nov 18;14:948848. doi: 10.3389/fnagi.2022.948848. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36466604 Free PMC article.
-
Olfactory ensheathing cells and neuropathic pain.Front Cell Dev Biol. 2023 Apr 5;11:1147242. doi: 10.3389/fcell.2023.1147242. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37223000 Free PMC article. Review.
References
REFERENCES
-
- Lewis PA. James Parkinson: the man behind the shaking palsy. J Parkinsons Dis. 2012;2(3):181-187.
-
- Carvey PM, Punati A, Newman MB. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant. 2006;15(3):239-250.
-
- Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron. 2015;85(2):257-273.
-
- Politis M, Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC Med. 2012;10(1):1.
-
- Chen W, Huang Q, Ma S, Li M. Progress in dopaminergic cell replacement and regenerative strategies for Parkinson’s disease. ACS Chem Neurosci. 2019;10(2):839-851.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical